Media Statement: Labcorp receives FDA Emergency Use Authorization for first COVID-19 test to identify specific SARS-CoV-2 lineages

BURLINGTON, N.C.,  June 14, 2022 — On Friday, June 10, 2022, Labcorp, a global life sciences company, received an emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its VirSeq SARS-CoV-2 NGS (next-generation sequencing) Test on the PacBio Sequel II sequencing system.

Labcorp expands access to comprehensive genomic testing through new lung cancer program

BURLINGTON, N.C. --(BUSINESS WIRE)--Jun. 2, 2022-- Labcorp (NYSE: LH), a leading global life sciences company, understands the important and growing role of precision medicine and is working to ensure more people have access to targeted and personalized treatments.

Labcorp signs statement of support for guard and reserve members

BURLINGTON, N.C., May 26, 2022 — North Carolina Employer Support of the Guard and Reserve (ESGR), a United States Department of Defense program, announced today that Labcorp, a global life sciences company, signed a Statement of Support for the Guard and Reserve at its corporate headquarters in Burlington, N.C. Representatives of Labcorp’s Veteran Employee Resource Group (VERG) and others attended this event in person and virtually.